Valuation: Brooks Laboratories Limited

Market Cap 1.09B 11.4M 10.02M 9.33M 8.57M 16.09M 16.3M 111M 43.3M 540M 42.79M 41.87M 1.87B P/E 2024
-12.2x
P/E 2025 -28.6x
Enterprise Value 1.17B 12.19M 10.71M 9.97M 9.16M 17.2M 17.42M 119M 46.29M 577M 45.74M 44.76M 1.99B EV / Sales 2024
3.16x
EV / Sales 2025 3.93x
Free-Float
44.12%
Yield 2024 *
-
Yield 2025 -
07-17 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
06-18 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/10/25 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/08/25 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
28/05/25 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/02/25 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
26/12/24 Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024 CI
10/12/24 Brooks Laboratories Limited announced that it expects to receive INR 750 million in funding from Jalan Chemical Industries Private Limited, K M Visaria Family Trust CI
1 day+2.73%
1 week-4.92%
Current month-4.35%
1 month-10.41%
3 months-2.43%
6 months-0.14%
Current year-17.82%
1 week 62.92
Extreme 62.92
70
1 month 62.92
Extreme 62.92
79
Current year 36.9
Extreme 36.9
82.3
1 year 36.9
Extreme 36.9
165.95
3 years 36.9
Extreme 36.9
202.8
5 years 36.9
Extreme 36.9
202.8
10 years 14.05
Extreme 14.05
202.8
Manager TitleAgeSince
Chief Executive Officer 58 22/01/2002
Chief Executive Officer - 31/05/2026
President 57 22/08/2023
Director TitleAgeSince
Director/Board Member 53 22/11/2022
Director/Board Member 62 09/09/2010
Director/Board Member - 22/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.73%-4.92% - - 19.6M
+1.68%+2.13%+16.17%+77.49% 48.36B
+1.52%+2.95%+60.39%+112.28% 35.8B
-0.09%-0.66%-8.03%+31.90% 11.83B
-0.05%-3.10%+13.50%+77.95% 11.48B
+0.56%-0.37%+37.53%+142.08% 9.01B
+0.18%+0.58%+49.62%-9.13% 6.99B
+0.95%-1.59%+12.34%+32.81% 6.7B
+0.18%-1.77%+2.36%+172.36% 6.42B
+3.51%-10.57%-31.55%+0.09% 5.3B
Average +1.12%-1.21%+16.93%+70.87% 15.77B
Weighted average by Cap. +1.17%-0.14%+25.51%+81.63%

Financials

2024 2025
Net sales 795M 8.29M 7.29M 6.78M 6.23M 11.7M 11.85M 80.62M 31.49M 392M 31.11M 30.44M 1.36B 826M 8.61M 7.57M 7.04M 6.47M 12.15M 12.31M 83.74M 32.7M 408M 32.32M 31.62M 1.41B
Net income -196M -2.04M -1.8M -1.67M -1.54M -2.88M -2.92M -19.87M -7.76M -96.74M -7.67M -7.5M -334M -99.67M -1.04M -914K -851K -781K -1.47M -1.49M -10.11M -3.95M -49.22M -3.9M -3.82M -170M
Net Debt 55.16M 575K 506K 471K 432K 812K 822K 5.6M 2.19M 27.24M 2.16M 2.11M 94.15M 75.39M 786K 691K 643K 591K 1.11M 1.12M 7.65M 2.99M 37.23M 2.95M 2.89M 129M
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Employees
323
Date Price Change Volume
27/07/26 65.95 +2.73% 269
24/07/26 ₹64.20 -4.92% 2,021
23/07/26 ₹67.52 +1.14% 253
22/07/26 ₹66.76 0.00% 222
21/07/26 ₹66.76 -1.82% 729